This Drug Cut LDL 56%—But That Wasn’t the Goal @nicknorwitzMDPhD
This Drug Cut LDL 56%—But That Wasn’t the Goal  @nicknorwitzMDPhD
Uploaded April 2026 | Updated September 2026, 1 week ago
Check out the long-form video: youtu.be/5idzP5ghT7A

Ezetimibe is typically seen as a cholesterol-lowering drug that works in the gut—but emerging evidence suggests it may also act in the brain. By interfering with a protein interaction linked to misfolding, it could play a role in processes relevant to neurodegeneration. Some data even show a lower risk of Alzheimer’s disease among users, though the evidence is still evolving.
For the full mechanisms, limitations, and nuance, watch the long-form video.

#Ezetimibe #Cholesterol #LDL #Neurodegeneration #AlzheimersResearch #BrainHealth #StayCurious
This Drug Cut LDL 56%—But That Wasn’t the GoalThe 20-Year-Old Cholesterol Study Everyone MissedWhy Visceral Fat Explodes in Middle AgeSardines in a Blizzard?! 12-HEPE Hormone and thermogenesis.Can Nattokinase Reverse Atherosclerosis?How the Gut Causes Stress EatingCan This Nut Make New Neurons?Why We Wanted to Retract Our Own PaperThis Sugar Science Blew Our Minds! (ft’ Dr. Andrew Koutnik)The Molecule Mimics Part of ExerciseMost People Stop Fasting Too SoonNew Study Pit Keto Against the Mediterranean Diet. Keto Won
Nick Norwitz MD PhD |

This Drug Cut LDL 56%—But That Wasn’t the Goal

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER